| Halaven (eribulin mesylate) / Eisai |
jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib |
|
|
| Active, not recruiting | 2 | 120 | Japan | Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene | Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development | Advanced soft tissue sarcoma | | | | |
NCT00413192 / 2005-004272-20: E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma |
|
|
| Completed | 2 | 128 | Europe | E7389 | Eisai Inc. | Soft Tissue Sarcoma | 06/12 | 02/13 | | |
NCT01458249: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217) |
|
|
| Completed | 2 | 52 | Japan | eribulin mesylate, E7389 | Eisai Co., Ltd. | Soft Tissue Sarcoma | 11/14 | 02/16 | | |
| Completed | 2 | 19 | Canada, US | Eribulin Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Pharmacological Study | National Cancer Institute (NCI) | Recurrent Osteosarcoma | 06/15 | 03/20 | | |
2018-004571-12: Trial in advanced Solitary Fibrous Tumor (SFT) Studio clinico nel Tumore Fibroso Solitario (TFS) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Eribulina, [30058], Solution for injection, HALAVEN - 0.44MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 2ML 6 FLACONCINI | ITALIAN SARCOMA GROUP, Eisai Italy | Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Advanced Solitary Fibrous Tumor (SFT) Tumore Fibroso Solitario in fase avanzata, Diseases [C] - Cancer [C04] | | | | |
NCT03441360 / 2018-001282-17: Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) |
|
|
| Completed | 2 | 23 | US | Eribulin mesylate | Eisai Inc. | Relapsed/Refractory Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma | 01/21 | 01/22 | | |
ACTRN12618000357257: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 5 substudy 10: Eribulin |
|
|
| Completed | 2 | 16 | | | The University of Sydney, Office for Health and Medical Research | Cancer
, Sarcoma, Angiosarcoma | | | | |
NCT03810976: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma |
|
|
| Completed | 2 | 37 | RoW | Eribulin, gemcitabine | Yonsei University | Sarcoma | 05/22 | 05/22 | | |
NCT03331250: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) |
|
|
| Active, not recruiting | 2 | 13 | US | Eribulin, Halaven | Massachusetts General Hospital, Eisai Inc. | Angiosarcoma, Epithelioid Hemangioendothelioma | 07/22 | 05/25 | | |
NCT03899805: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas |
|
|
| Active, not recruiting | 2 | 57 | US | Eribulin, Halaven, Pembrolizumab, Keytruda | Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC | Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma | 08/25 | 08/25 | | |
ChiCTR2200059629: Eribulin plus anlotinib for the treatment of refractory and advanced soft tissue sarcoma after failure of standard therapy：a prospective, open-label, single arm and single center clinical study |
|
|
| Recruiting | 2 | 30 | | Eribulin plus anlotinib | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, partly self-funded，partly provied by Eisai China Inc. | Soft tissue Sarcoma | | | | |
| Recruiting | 2 | 16 | Europe | Eribulin, Intervention under investigation | Italian Sarcoma Group, Eisai Inc. | Solitary Fibrous Tumor | 04/24 | 04/24 | | |
| Recruiting | 2 | 30 | Europe, Canada, RoW | Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda | Australia New Zealand Gynaecological Oncology Group, Eisai Inc., Merck Sharp & Dohme LLC | Ovarian Carcinosarcoma, Uterine Carcinosarcoma | 12/24 | 12/26 | | |
ChiCTR2300072293: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin |
|
|
| Recruiting | 2 | 30 | | zimberelimab administered in combination with anlotinib and eribulin | Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital, selt-funded | soft tissue sarcoma | | | | |
ChiCTR2300067650: Safety and efficacy of eribulin combined with anlotinib followed by anlotinib maintenance in advanced soft tissue sarcoma patients with intolerance or failure of doxorubicin-based chemotherapy: a prospective single-arm phase II study |
|
|
| Not yet recruiting | 2 | 30 | | Treatment with eribulin and anlotinib | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No | Soft-Tissue Sarcoma | | | | |
TEASTS, ChiCTR2300071221: Efficacy of Tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult soft tissue sarcoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab + iribrin + arotinib | Zhongshan Hospital, Fudan University ; Zhongshan Hospital, Fudan University, Zhongguancun Foundation | soft tissue sarcoma (STS) | | | | |
NCT03245450 / 2016-003352-67: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors |
|
|
| Completed | 1/2 | 40 | Europe | Eribulin mesilate, E7389, Irinotecan hydrochloride, (S)-4,11-diethyl-39 3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-4-yl-[1,4'-bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate | Eisai Inc. | Refractory or Recurrent Solid Tumors, Rhabdomyosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Ewing Sarcoma | 05/21 | 05/21 | | |
| Active, not recruiting | 1/2 | 30 | RoW | Eribulin, Halaven, Lenvatinib, Lenvima | National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan | Leiomyosarcoma, Liposarcoma, Soft Tissue Sarcoma Adult, Advanced Cancer | 06/21 | 06/23 | | |
NCT06006273: A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors |
|
|
| Recruiting | 1/2 | 48 | US | Eribulin, Irinotecan, Temozolomide | M.D. Anderson Cancer Center | Refractory Solid Tumors | 12/26 | 12/28 | | |
